Abstract: Systems and methods are configured to provide and manage an electronic bill of lading (eBOL) for a shipment of goods. Various embodiments involve generating an eBOL upon receiving a request from a stakeholder in the shipment of goods. Here, the eBOL is generated from information stored in centralized storage media and is configured as a split screen that includes an interactive panel having fields to enter information and a panel that includes a formal version of the eBOL. The eBOL is displayed on a webpage, browser, interface accessible by the stakeholder so that the stakeholder can enter the information for the fields. Upon doing so, the information stored in the centralized storage media is updated to reflect the information entered by the stakeholder and any subsequent requests from other stakeholders in the shipment of the goods results in displaying the eBOL with the information entered by the stakeholder.

Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

Abstract: A push-to-talk over cellular (PoC) system is provided in which a negative indication-to-speak may be delivered to a requesting unit when the requested wireless unit is not available. In one embodiment of the instant invention, a first wireless unit is paged in response to receiving a request from the second wireless unit to transmit a message to the first wireless unit. A page response signal is received from the first wireless unit, and the negative indication-to-speak to the second wireless unit is delivered to the second wireless unit in response to receiving the page response signal.

Abstract: The method described herein is useful in a push-to-talk over cellular (PoC) system to provide an accurate but low-latency indication-to-speak. Generally, the method may be referred to as a page-event confirmed indication-to-speak. The page-event confirmed indication-to-speak accurately confirms a targeted but dormant mobile station is within radio reach by first sending a paging message to the dormant mobile station. When the dormant mobile station responds to the page message, an indication-to-speak is delivered to an initiating mobile station to indicate to the user that he/she may now speak.